3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Other hematologic neoplasm
1
Gynecologic
1
Gastrointestinal
1
Dermatologic
1
Conditions
Carcinoma, Basal Cell
8
Medulloblastoma
6
Recurrence
4
Skin Neoplasms
3
Basal Cell Nevus Syndrome
3
Thrombocythemia, Essential
2
Prostatic Neoplasms
2
Primary Myelofibrosis
2
Polycythemia Vera
2
Pancreatic Neoplasms
2
Ovarian Neoplasms
2
Neoplasm Metastasis
2
Multiple Myeloma
2
Lung Neoplasms
2
Leukemia, Myeloid, Acute
2
Glioma
2
Glioblastoma
2
Carcinoma, Hepatocellular
2
Breast Neoplasms
2
Astrocytoma
2
Thrombocytosis
1
Stomach Neoplasms
1
Squamous Cell Carcinoma of Head and Neck
1
Rhabdomyosarcoma
1
Rhabdoid Tumor
1
Pyloric Stenosis, Hypertrophic
1
Precursor Cell Lymphoblastic Leukemia-Lymphoma
1
Pinealoma
1
Pancreatic Ductal Adenocarcinoma
1
Pancreatic Diseases
1
Interventions
Fluorouracil
218
Leucovorin
201
Oxaliplatin
191
Irinotecan
148
Bevacizumab
107
Capecitabine
93
Cetuximab
89
Folfox protocol
54
Chemotherapy, Adjuvant
34
Panitumumab
30
pembrolizumab
23
Nivolumab
22
Colonoscopy
22
Gemcitabine
20
Magnetic Resonance Spectroscopy
19
Floxuridine
19
IFL protocol
18
Celecoxib
18
Radiotherapy
17
Neoadjuvant Therapy
17
Early Intervention, Educational
17
Drug Therapy
17
Laparoscopy
14
Cyclophosphamide
14
Counseling
14
trifluridine tipiracil drug combination
13
regorafenib
13
XELOX
13
Exercise
13
Erlotinib Hydrochloride
13
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Interventional
×
Colonic Neoplasms
×
sonidegib
×
Clear all
NCT02002689
2016-05-02
SIGNATURE
Novartis
Phase 2
Terminated
10 enrolled
9 charts